^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PF-07224826

    i
    Other names: PF-07224826
    Associations

    News

    Trials
    Company:
    Pfizer
    Drug class:
    CDK4 inhibitor, CDK6 inhibitor, CDK2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    1year
    Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=0, Withdrawn, Pfizer | N=110 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    fulvestrant • PF-07224826
    over1year
    Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=110, Not yet recruiting, Pfizer | Trial completion date: Oct 2027 --> Apr 2028 | Initiation date: Jul 2023 --> Jan 2024 | Trial primary completion date: Oct 2025 --> Apr 2026
    Trial completion date • Trial initiation date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    fulvestrant • PF-07224826
    over1year
    Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=110, Not yet recruiting, Pfizer
    New P1 trial • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    fulvestrant • PF-07224826